Contineum Therapeutics, Inc. (CTNM:NASDAQ) closed at $8.31 on October 23, 2026, down 1.01% on the day. The stock trades 53.3% below its 52-week high of $17.79 and 23.6% above its 52-week low of $6.73. Over the past year, it lost 24.8%. Contineum Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, CTNM closed higher on 121 days (48%). Its best day was January 13, 2026 (+18.87%) and its worst was October 12, 2026 (-35.99%). The stock moved 10% or more in a single session 11 times.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Find more stocks like CTNM with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.